Status:
COMPLETED
Contrast-enhanced 3D T1-weighted Gradient-echo Versus Spin-echo 3 Tesla MR Sequences in the Detection of Active Multiple Sclerosis Lesions
Lead Sponsor:
Fondation Ophtalmologique Adolphe de Rothschild
Conditions:
Magnetic Resonance Imaging
Central Nervous System
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Gadolinium-enhanced magnetic resonance imaging (MRI) is currently the imaging gold standard to detect active inflammatory lesions in multiple sclerosis (MS) patients. The sensitivity of enhanced MRI t...
Eligibility Criteria
Inclusion
- Equal or more than 18 years of age
- Able to provide written informed consent.
- Known central nervous system inflammatory disease
- Magnetic Resonance exam needed for evaluation after a clinical event in the last 3 weeks
Exclusion
- Current treatment with dimethylfumarate (Tecfidera®), natalizumab (Tysabri®) or fingolimod (Gilenya®)
- Contraindications either to 3 Tesla Magnetic Resonance Imaging (e.g. certain metallic and electronic implants, claustrophobia) or IV gadolinium contrast (allergy, pregnancy, breast-feeding, renal insufficiency).
Key Trial Info
Start Date :
August 2 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 26 2021
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT03268239
Start Date
August 2 2017
End Date
April 26 2021
Last Update
January 6 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondation Ophtalmologique A. de Rothschild
Paris, France, France, 75019